Genprex, Inc. (GNPX)
| Market Cap | 4.22M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -30.86M |
| Shares Out | 1.91M |
| EPS (ttm) | -22.56 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 23,115 |
| Open | 2.170 |
| Previous Close | 2.120 |
| Day's Range | 2.090 - 2.329 |
| 52-Week Range | 2.090 - 42.400 |
| Beta | -0.63 |
| Analysts | Strong Buy |
| Price Target | 10.00 (+362.96%) |
| Earnings Date | May 20, 2024 |
About GNPX
Genprex, Inc., a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes. Its lead product candidate is REQORSA (GPX-001) that is in Phase 1/2 and 2 clinical trials to treat non-small cell lung cancer and small cell lung cancer. The company is also developing GPX-002 for the treatment of type 1 diabetes, and GPX-003 for the treatment of type 2 diabetes. Genprex, Inc. was incorporated in 2009 and is headquartered in Austin, Texas. [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to one analyst, the rating for GNPX stock is "Strong Buy" and the 12-month stock price forecast is $10.0.
News
Genprex Collaborators Report Positive Preclinical Data on the Use of Reqorsa® and on NPRL2 Gene Therapy Utilizing Non-Viral Oncoprex® Delivery System for the Treatment of Lung Cancers at the 2024 AACR Annual Meeting
Compelling Data Validates the Potential of Reqorsa® Immunogene Therapy and the Oncoprex® Delivery System as Innovative Cancer Treatments REQORSA Has Anti-Tumor Mechanisms and Ability to Trigger Cancer...
Genprex Expands Clinical Trial Sites for Acclaim-3 Clinical Study of Reqorsa® Therapy in Combination with Tecentriq® to Treat Small Cell Lung Cancer
Multiple clinical trial sites to be opened under collaboration with large network of community-based oncology practices Acclaim-3 Study Supported by FDA Orphan Drug and Fast Track Design...
Genprex Collaborators Publish Positive Preclinical Data with NPRL2 Gene Therapy Utilizing Oncoprex® Delivery System
NPRL2 Gene Therapy Induces Anti-Tumor Activity in Anti-PD1 Resistant KRAS/STK11 Mutant Non-Small Cell Lung Cancer in a Humanized Mouse Model Provides Additional Preclinical Validation of Oncoprex® Del...
Genprex Announces Closing of $6.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
AUSTIN, Texas , March 22, 2024 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patien...
Genprex Announces $6.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
AUSTIN, Texas , March 19, 2024 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patien...
Genprex Receives Notice of Patent Grant for Korean Patent Claiming Reqorsa® Immunogene Therapy with PD-1 and PD-L1 Antibodies to Treat Cancers
Expands on the previously granted patents covering the use of REQORSA in combination with immune checkpoint inhibitors applicable to Genprex's Acclaim-2 and Acclaim-3 clinical trials AUSTIN, Texas , M...
Genprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa® and on NPRL2 Gene Therapy Utilizing Non-Viral Oncoprex® Delivery System for the Treatment of Lung Cancers at the 2024 AACR Annual Meeting
Reqorsa® Immunogene Therapy May be a Potential Therapy for ALK-Positive Lung Cancer REQORSA has Anti-Tumor Mechanisms that Target and Disrupt the Metabolism of Cancer Cells NPRL2 Gene Therapy Induces ...
Genprex Expands Nonclinical Programs into New Therapeutic Indications with Research Collaborators
Reqorsa® Therapy May Be Potential Treatment for ALK-Positive Lung Cancer Three Collaborators Selected to Present Positive Nonclinical Data on Genprex Oncology Program at the 2024 American Association ...
Genprex to Present at Upcoming BIO CEO & Investor Conference
Presentation to Highlight Company's Gene Therapies for Cancer and Diabetes AUSTIN, Texas , Feb. 6, 2024 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene...
Genprex Announces First Patient Dosed in Phase 2a Expansion of Acclaim-1 Clinical Study of Reqorsa® Therapy in Combination with Tagrisso® to Treat Non-Small Cell Lung Cancer
Expects to Complete Enrollment of Phase 2a Expansion Study by the end of 2024 Acclaim-1 Study Has FDA Fast Track Designation AUSTIN, Texas , Feb. 5, 2024 /PRNewswire/ -- Genprex, Inc. ("Genprex" or th...
Genprex Announces 1-for-40 Reverse Stock Split Effective February 2, 2024
AUSTIN, Texas , Jan. 31, 2024 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patient...
Genprex Provides Business Update and Outlook for 2024
Acclaim-1 Phase 2a and Acclaim-3 Phase 1 clinical studies opening for enrollment in January 2024 Poised for FDA guidance regarding diabetes gene therapy program in 2024 AUSTIN, Texas , Jan. 5, 2024 /P...
Genprex to Present at BIO-Europe 2023 Conference
Presentation to be held on Tuesday, November 7, 2023 from 4:45 – 5:00 p.m. UTC AUSTIN, Texas , Nov. 1, 2023 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage...
Genprex to Host a Virtual Key Opinion Leader Event on "Bringing Gene Therapy to the Fight Against Lung Cancers"
Webinar to be held on Friday, October 27, 2023 from 12:30 pm - 1:45 pm Eastern Time AUSTIN, Texas , Oct. 20, 2023 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-...
Genprex to Present Data on the Use of REQORSA® for the Treatment of Lung Cancers at 2023 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
Acclaim-1 Phase 1 study had no Dose Limiting Toxicity, and results establish Phase 2 Recommended Dose as well as provide data showing efficacy of REQORSA® in combination with Tagrisso® Preclinical res...
Genprex Inc. (NASDAQ: GNPX) Receives Orphan Drug Designation for Immunogene Therapy for Treatment of SCLC
NEW YORK, Sept. 21, 2023 (GLOBE NEWSWIRE) -- via InvestorWire — Genprex Inc. (NASDAQ: GNPX) today announces its placement in an editorial published by NetworkNewsWire ("NNW"), one of 50+ trusted brand...
Genprex to Present at Upcoming September Investor Conference
Presentation to Highlight Company's Gene Therapies for Cancer and Diabetes AUSTIN, Texas , Sept. 7, 2023 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gen...
Genprex Appoints Suzanne Thornton-Jones as Senior Vice President, Regulatory Affairs
Strengthens management team with seasoned regulatory expert to support pipeline of gene therapies for the treatment of cancer and diabetes, including two clinical trials in Non-Small Cell Lung Cancer ...
Genprex Granted FDA Orphan Drug Designation (ODD) for REQORSA® Immunogene Therapy for the Treatment of Small Cell Lung Cancer
ODD is in addition to Three FDA Fast Track Designations Genprex expects to dose the first patient in the Acclaim-3 clinical trial in the fourth quarter of 2023 AUSTIN, Texas , Aug. 10, 2023 /PRNe...
Genprex Announces Closing of $7.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
AUSTIN, Texas , July 21, 2023 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patient...
Genprex Announces $7.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
AUSTIN, Texas , July 19, 2023 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patient...
Genprex Signs Exclusive License to Additional Diabetes Technology with the University of Pittsburgh
Latest license creates a comprehensive panel of gene therapies exclusively licensed by Genprex for the Company's diabetes gene therapy program Innovative program supported by preclinical data shows st...
Gene Therapy Company Genprex, Inc. (NASDAQ: GNPX) Receives Fast Track Designation From The FDA For Its Small Cell Lung Cancer Drug Candidate
AUSTIN, TX / ACCESSWIRE / July 11, 2023 / The U.S. Food and Drug Administration (FDA) recently granted Fast Track Designation (FTD) for REQORSA® Immunogene Therapy for patients with extensive-stage sm...
Genprex Granted Chinese Patent for REQORSA® Immunogene Therapy in Combination with PD-1 Antibodies to Treat Cancers
Provides Additional Protection in Large Markets for Therapeutic Combination in Acclaim-2 Phase 1/2 Clinical Trial Patent Already Granted for Same Combination in U.S. Japan, Australia, Russia and Mexi...
Genprex Receives U.S. FDA Fast Track Designation for REQORSA® Immunogene Therapy in Combination with Tecentriq® for the Treatment of Small Cell Lung Cancer
Third FDA Fast Track Designation Further Validates the Potential of REQORSA AUSTIN, Texas , June 28, 2023 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage ge...